Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
If approved in the European Union, Fruquintinib will be the first novel targeted therapy for Metastatic Colorectal Cancer regardless of biomarker status in over a decade
Sales reflect continued strong growth in oncology and vaccines
Subscribe To Our Newsletter & Stay Updated
